Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said investigators dosed the first patient in its Phase 1 trial of PolyPEPI™ 1018, the company’s investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).

Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said it had successfully activated its clinical trial site at the Mayo Clinic in Rochester, Minnesota for its Phase 1 trial of PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC).

Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today named Gábor Illés as its Chief Financial Officer. Mr. Illés has served as a non-executive investor director of Treos since the company’s inception.

Treos Bio Limited, an immuno-oncology company developing next-generation, off-the-shelf precision cancer vaccines coupled with companion diagnostics, today said that the U.S. Food and Drug Administration has accepted its Investigational New Drug (IND) Application for PolyPEPI™ 1018, its investigational precision cancer vaccine for patients with metastatic colorectal cancer (mCRC), and has provided authorization to proceed with the Phase 1 study in mCRC patients.

Treos Bio Limited, which is developing precision peptide cancer vaccines coupled with companion diagnostics, today announced it has entered into an agreement with Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization. As part of the agreement, PPD® Biotech, a PPD service dedicated to biotech and small to mid-sized pharmaceutical companies, will manage Treos Bio’s first-in-man study of its lead therapeutic cancer vaccine for metastatic colorectal cancer. This study will be conducted in the United States and Europe.

Treos Bio, Ltd., which is developing precision cancer immunotherapies paired to companion diagnostics, today announced it completed an $8 million funding through a group of private investors.